🇺🇸 PTCT — PTC Therapeutics, Inc.

Salud Compra
← Volver

Precio actual

68,12 USD

Máx. histórico

89,55

117 días

Caída desde máximo

-23,93%

Rango 52 semanas

58,80 – 90,87

Variación hoy

+11,89%

Cierre anterior

60,88

Rango de hoy

63,16 – 68,72

Volumen hoy

2.643.738

Peor caída histórica

-94,60%

17/03/2015 → 03/11/2016

Recuperado en 3305 días

Volatilidad anualizada ⓘ

72,99%

Información
Nombre completo
PTC Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
991
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
100,47 USD (puede no estar actualizado)
Primera cotización
20/06/2013
Precio actualizado
hace 12 horas
Sobre la empresa

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
03/04/2023 48,18 49,67 47,09 47,43 -2,09% 5,34% 726.400
31/03/2023 49,11 50,20 48,30 48,44 -0,86% 3,87% 785.700
30/03/2023 48,48 49,09 47,72 48,86 +1,39% 2,83% 640.900
29/03/2023 45,34 48,33 45,00 48,19 +6,80% 7,34% 603.300
28/03/2023 45,74 46,66 44,58 45,12 -1,40% 4,55% 643.200
27/03/2023 44,33 46,40 43,65 45,76 +3,60% 6,20% 814.700
24/03/2023 45,27 45,42 42,27 44,17 -5,36% 6,96% 1.977.500
23/03/2023 46,76 47,19 45,82 46,67 +0,69% 2,93% 498.400
22/03/2023 48,28 48,28 46,30 46,35 -4,35% 4,10% 646.200
21/03/2023 48,77 49,26 47,93 48,46 -0,06% 2,72% 744.200
20/03/2023 47,41 48,79 47,09 48,49 +2,52% 3,58% 442.200
17/03/2023 47,49 47,69 45,01 47,30 -1,66% 5,64% 1.472.900
16/03/2023 46,49 48,33 45,67 48,10 +2,91% 5,72% 514.600
15/03/2023 46,43 47,21 45,02 46,74 -0,47% 4,72% 815.700
14/03/2023 47,11 47,51 46,04 46,96 +1,91% 3,12% 676.100
13/03/2023 43,75 47,44 43,75 46,08 +4,18% 8,43% 795.200
10/03/2023 45,76 45,76 43,00 44,23 -3,72% 6,03% 1.094.400
09/03/2023 48,47 48,74 45,62 45,94 -4,67% 6,44% 1.079.300
08/03/2023 47,37 48,24 47,00 48,19 +1,86% 2,62% 986.900
07/03/2023 45,64 47,73 45,21 47,31 +3,80% 5,52% 833.100
06/03/2023 46,16 46,56 45,14 45,58 -1,13% 3,07% 413.800
03/03/2023 44,86 46,45 43,97 46,10 +3,11% 5,52% 796.300
02/03/2023 44,79 45,15 43,94 44,71 -1,17% 2,70% 509.500
01/03/2023 43,70 46,14 42,69 45,24 +3,60% 7,89% 1.005.000
28/02/2023 42,24 43,89 42,24 43,67 +3,51% 3,91% 673.200
27/02/2023 43,25 44,11 42,12 42,19 -2,43% 4,60% 736.100
24/02/2023 43,09 43,91 42,94 43,24 -0,64% 2,25% 611.900
23/02/2023 44,08 46,11 42,26 43,52 -1,61% 8,73% 506.300
22/02/2023 45,85 45,85 41,02 44,23 -1,10% 10,53% 1.052.100
21/02/2023 46,29 46,44 44,72 44,72 -4,20% 3,70% 824.400